Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Net: 2023-2025

Historic Receivables - Net for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $3.5 million.

  • Tonix Pharmaceuticals Holding's Receivables - Net fell 13.26% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 13.26%. This contributed to the annual value of $3.7 million for FY2024, which is 19.76% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Receivables - Net of $3.5 million as of Q3 2025, which was up 50.04% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Receivables - Net ranged from a high of $4.6 million in Q4 2023 and a low of $1.6 million during Q3 2023.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Receivables - Net averaged around $3.3 million, with its median value being $3.4 million (2024).
  • In the last 5 years, Tonix Pharmaceuticals Holding's Receivables - Net spiked by 156.91% in 2024 and then plummeted by 30.52% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Receivables - Net (Quarterly) stood at $4.6 million in 2023, then fell by 19.76% to $3.7 million in 2024, then fell by 13.26% to $3.5 million in 2025.
  • Its Receivables - Net was $3.5 million in Q3 2025, compared to $2.3 million in Q2 2025 and $3.3 million in Q1 2025.